by Emily Jones | Jun 28, 2022 | Neurology News, News, Nursing News, Orthopedics News, Pediatricians News, Physical Therapists News, Pulmonologist News, Radiology News, slider, Social Worker News
There are many different modalities and activities that have been successful in progressing Michael, our patient with SMA, towards reaching his goals of less pain during activities as well as increased independence. Over the past four years, we have attempted many...
by Steve Bryson PhD | Jun 20, 2022 | News
MicroRNAs isolated from the bloodstream of patients with infant-onset spinal muscular atrophy (SMA) type 1 before treatment were related to functional responses to Spinraza (nusinersen) after six months of therapy, a study suggested. Researchers said these microRNAs...
by Marta Figueiredo PhD | Jun 17, 2022 | News
Pediatric neurologists’ expectations in terms of treatment benefits are decidedly higher for infants and toddlers with spinal muscular atrophy (SMA) types 1 and 2 than for adolescent patients, a study in Spain shows. Notably, neurologists with low aversion to...
by Marisa Wexler MS | Jun 15, 2022 | News
The total medical costs associated with spinal muscular atrophy (SMA) are lower for patients diagnosed at birth via newborn screening, compared with those diagnosed after they start showing symptoms of the disease, a new study has found. These findings “demonstrate...
by Marisa Wexler MS | Jun 13, 2022 | News
The newborn screening program at Cadham Provincial Laboratory in Manitoba, Canada, is expanding to include spinal muscular atrophy (SMA), according to an announcement from Audrey Gordon, the province’s health minister. “Early diagnosis is the key to improving outcomes...
by Steve Bryson PhD | Jun 10, 2022 | News
A new modeling study predicts that higher doses of Spinraza (nusinersen) may improve its effectiveness compared with the approved 12 mg dose. The study used data from two clinical trials that evaluated the disease-modifying therapy in infants with spinal muscular...